RGRX (Regenerx Biopharmaceuticals) Market Cap: $0.00 Mil (As of Jul. 04, 2026)


What is Regenerx Biopharmaceuticals Market Cap?

Regenerx Biopharmaceuticals RGRX Market Cap is $0.00 Mil as of Jul. 04, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Regenerx Biopharmaceuticals's share price for the quarter that ended in Mar. 2023 was $10.5. Regenerx Biopharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2023 was 1.44 Mil. Therefore, Regenerx Biopharmaceuticals's market cap for the quarter that ended in Mar. 2023 was $15.07 Mil.

Regenerx Biopharmaceuticals's quarterly market cap declined from Sep. 2022 ($20.09 Mil) to Dec. 2022 ($19.93 Mil) and declined from Dec. 2022 ($19.93 Mil) to Mar. 2023 ($15.07 Mil).

Regenerx Biopharmaceuticals's annual market cap declined from Dec. 2020 ($59.36 Mil) to Dec. 2021 ($22.96 Mil) and declined from Dec. 2021 ($22.96 Mil) to Dec. 2022 ($19.93 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regenerx Biopharmaceuticals's Enterprise Value for Today is $0.24 Mil.

Regenerx Biopharmaceuticals  (OTCPK:RGRX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Regenerx Biopharmaceuticals Market Cap Related Terms

Regenerx Biopharmaceuticals Market Cap Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Market Cap Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.90 18.41 59.36 22.96 19.93

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.83 22.24 20.09 19.93 15.07

RGRX vs MYMX, RGMP, NBRVF: Market Cap Comparison

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerx Biopharmaceuticals Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Market Cap falls into.


Regenerx Biopharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Regenerx Biopharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$13.89*1.435
=$19.93

Regenerx Biopharmaceuticals's Market Cap for the quarter that ended in Mar. 2023 is calculated as

Market Cap (Q: Mar. 2023 )=Share Price (Q: Mar. 2023 )*Shares Outstanding (EOP) (Q: Mar. 2023 )
=$10.5*1.435
=$15.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.00 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Market Cap of $0.00 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Market Cap too high?
Regenerx Biopharmaceuticals' current Market Cap is $0.00 Mil.
How does Regenerx Biopharmaceuticals' Market Cap compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regenerx Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerx Biopharmaceuticals's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Market Cap is $0.00 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.